CN Patent

CN107427511A — 包含n‑(3,5‑二甲氧基苯基)‑n’‑(1‑甲基乙基)‑n‑[3‑(1‑甲基‑1h‑吡唑‑4‑基)喹喔啉‑6‑基]乙烷‑1,2‑二胺的药物组合物

Assigned to Astex Therapeutics Ltd · Expires 2017-12-01 · 8y expired

What this patent protects

本发明涉及包含N‑(3,5‑二甲氧基苯基)‑N'‑(1‑甲基乙基)‑N‑[3‑(1‑甲基‑1H‑吡唑‑4‑基)喹喔啉‑6‑基]乙烷‑1,2‑二胺或其药学上可接受的盐或其溶剂合物的药物组合物；制备所述组合物的方法和所述组合物在制备用于预防或治疗，特别是治疗疾病例如癌症的药物中的用途。

USPTO Abstract

本发明涉及包含N‑(3,5‑二甲氧基苯基)‑N'‑(1‑甲基乙基)‑N‑[3‑(1‑甲基‑1H‑吡唑‑4‑基)喹喔啉‑6‑基]乙烷‑1,2‑二胺或其药学上可接受的盐或其溶剂合物的药物组合物；制备所述组合物的方法和所述组合物在制备用于预防或治疗，特别是治疗疾病例如癌症的药物中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN107427511A
Jurisdiction
CN
Classification
—
Expires
2017-12-01
Drug substance claim
No
Drug product claim
No
Assignee
Astex Therapeutics Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.